Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

• 出版年: Dermatology Reports
• 主要な著者: Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini
• フォーマット: 論文
• 言語: 英語
• 出版事項: PAGEPress Publications 2025-07-01
• 主題: Psoriasis; risankizumab; erythrodermic psoriasis; safety; efficacy
• オンライン･アクセス: https://www.pagepress.org/journals/dr/article/view/10379
• ISSN: 2036-7392; 2036-7406

Erythrodermic psoriasis (EP) is a severe and complex form of psoriasis. While risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in patients with moderate-to-severe plaque psoriasis, its effectiveness in patients with EP remains less explored. The literature contains several small studies and case reports that provide evidence for the potential use of biologic therapies in the treatment of erythrodermic psoriasis. This case series suggests that risankizumab may represent an effective and sustainable treatment option for patients with a history of EP.